| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
|
Medicine details |
|
| Medicine name | selinexor (Nexpovio®) |
| Formulation | oral |
| Reference number | 5131 |
| Indication | In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Company | Karyopharm Therapeutics |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/07/2022 |
| NICE guidance | TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |